Abstract not found

Despite improved rational drug design and a remarkable progress in genomic, proteomic and highthroughput screening methods, the number of novel, single-target drugs fell much behind expectations during the past decade. Multi-target drugs multiply the number of pharmacologically relevant target molecules by introducing a set of indirect, network-dependent effects. Parallel with this the low-affinity binding of multi-target drugs eases the constraints of druggability, and significantly increases the size of the druggable proteome. These effects tremendously expand the number of potential drug targets, and will introduce novel classes of multi-target drugs with smaller side effects and toxicity. Here we review the recent progress in this field, compare possible network attack strategies, and propose several methods to find target-sets for multi-target drugs.

Discovering functional gene expression patterns in the metabolic

Using gene expression data and network topology to detect substantial pathways, clusters and switches during oxygen

Ranked prediction of p53 targets using hidden variable dynamic modeling

This is an Open Access article distributed under the terms of the Creative Commons Attribution License

Research article Constructing disease-specific gene networks using pair-wise relevance metric: Application to colon cancer identifies interleukin 8, desmin and enolase 1 as the central elements

© 2007 Sun et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License

Salivary gland branching morphogenesis: a quantitative systems

This is an Open Access article distributed under the terms of the Creative Commons Attribution License